For Immediate Release: November 18, 2015

Mary Kuramoto
513-579-9911 x2523

Medpace recognized as a member of the Deloitte Cincinnati USA 100 for the 8th consecutive year

Cincinnati, OH ( November 18, 2015) – Medpace, Inc., a leading full-service global clinical research organization (CRO), today announced that they were recognized as a member of the Deloitte Cincinnati USA 100, coming in at number 34 for outstanding revenue growth as a member of the top 100 privately held companies in the Cincinnati area. Regional companies in the greater Cincinnati area are ranked by annual sales revenue to arrive at the 100 largest, privately held companies in Cincinnati, Ohio, and the surrounding business region.

Medpace founded in 1992 has experienced rapid growth, having built a state of the art research campus in Madisonville at the corner of Madison and Red Bank Expressway. The campus houses close to 1000 Medpace employees in the Corporate HQ, CRO, Labs, and Clinical Pharmacology Unit. Medpace continues to build jobs locally and abroad in the life science sector.

This is the eighth consecutive year for Medpace to be honored in the top 100 companies as a top privately held organization headquartered in Cincinnati Ohio.


Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2300 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information, please visit